Cancer
-
Comparative Study
Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
This study was conducted to assess the effectiveness of the 1997 American Joint Committee on Cancer (AJCC) staging system to predict survival and local control of patients with maxillary sinus carcinoma and to identify significant factors for overall survival, local control, and distant metastases in patients with these tumors. ⋯ The 1997 AJCC staging system was found to be superior to the 1977 AJCC staging system in predicting both survival and local control in this patient population. Combined surgical and radiation treatment to the primary tumor yielded higher survival and local control than radiotherapy alone. Other significant prognostic factors for survival were patient age, gender, and lymph node (N) classification. Prolonged overall radiation time was associated with poorer survival and local control. Late severe toxicity from the treatment of these tumors was a significant problem in long term survivors. Improved radiotherapy techniques should lead to decreased injury to the surrounding normal tissues. (c) 1999 American Cancer Society.
-
Review Comparative Study
Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials.
The early detection of gastric carcinoma is neither feasible nor practiced around the world, except on a limited basis in Japan. Thus, because gastric carcinoma is detected later in most patients throughout the world, those who undergo curative resection still remain at high risk for relapse. Adjuvant therapy therefore has a potentially important place in the treatment of these patients. It has been extensively investigated in the Orient, North America, and Europe. The authors reviewed the results of these trials to determine the current status of adjuvant therapy. ⋯ Postoperative chemotherapy as an adjuvant to potentially curative resection of gastric carcinoma remains investigational despite more than 30 years of investigation in the West. Newer therapeutic combinations or strategies (preoperative chemotherapy or chemoradiotherapy) have the potential to benefit the high risk patients.